论文部分内容阅读
目的:探讨支原体单克隆抗体PD4与黏附分子CD44v6、CD44v9蛋白在人喉癌组织中的表达及临床意义。方法:采用免疫组织化学Envision法检测212例喉不同病变组织标本(喉癌137例,喉癌前病变26例,声带息肉34例和癌周正常喉组织15例)中PD4、CD44v6、CD44v9蛋白的表达。结果:①PD4、CD44v6、CD44v9在人喉癌组织中表达阳性率分别为45.3%(62/137)、72.3%(99/137)、56.2%(77/137),明显高于其他喉不同病变组织(均P<0.01)。②中晚期(Ⅲ~Ⅳ期)、伴颈淋巴结转移的喉癌组织中PD4、CD44v6、CD44v9阳性表达率均显著高于早期(Ⅰ~Ⅱ期)和无颈淋巴结转移的喉癌组织(均P<0.01);喉癌术后3年或5年存活患者PD4、CD44v6、CD44v9表达阳性率明显低于生存时间未达3~5年者(P<0.01或P<0.05)。③PD4和CD44v6、CD44v9在人喉癌组织中联合表达阳性率为27.7%(38/137),显著高于喉其他不同病变组织中联合表达阳性率(5.3%,4/75)(P<0.01)。结论:喉癌的发生、发展及预后与PD4、CD44v6、CD44v9联合表达密切相关。
Objective: To investigate the expression and clinical significance of mycoplasma monoclonal antibody PD4 and adhesion molecules CD44v6 and CD44v9 in human laryngeal carcinoma. Methods: The expressions of PD4, CD44v6 and CD44v9 proteins in 212 samples of laryngeal tissues (137 cases of laryngeal carcinoma, 26 cases of laryngeal precancerous lesions, 34 cases of vocal cord polyps and 15 cases of normal laryngeal tissues) were detected by immunohistochemistry Envision method expression. Results: ①The positive rates of PD4, CD44v6 and CD44v9 in human laryngeal carcinoma were 45.3% (62/137), 72.3% (99/137) and 56.2% (77/137), respectively, which were significantly higher than those in other laryngeal tissues (All P <0.01). ② The positive expression rates of PD4, CD44v6 and CD44v9 in the advanced (stage Ⅲ ~ Ⅳ) laryngeal carcinoma with cervical lymph node metastasis were significantly higher than those in the early stage (stage Ⅰ ~ Ⅱ) and without lymph node metastasis (both P <0.01). The positive rates of PD4, CD44v6 and CD44v9 in patients with laryngeal cancer who survived 3 years or 5 years after operation were significantly lower than those with survival time less than 3 to 5 years (P <0.01 or P <0.05). (3) The positive rate of co-expression of PD4, CD44v6 and CD44v6 in human laryngeal squamous cell carcinoma was 27.7% (38/137), which was significantly higher than that in other laryngeal tissues (5.3%, 4/75) . Conclusion: The occurrence, development and prognosis of laryngeal carcinoma are closely related to the joint expression of PD4, CD44v6 and CD44v9.